Ideally, using both RNA-seq and ChIP-seq techniques, in different types of cells in the context of TAC-induced PAH, then verified by a lineage or organ-specific EZH2 knockout or transgenic model, would hopefully render a more solid decision to target EZH2 for drug development. Here, EZH2 is linked to pulmonary arterial hypertension.